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The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle
threshold (CT) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evalu-
ated the relationship between Xpert CT trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential
utility of Xpert CT for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary
TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tubercu-
losis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to
20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal CT data were modeled using a nonlin-
ear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change
of CTwas higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine expo-
sure, but not assigned dose, was significantly associated with rate of change in CT (P 0.02). The estimated increase in CT slope
for every additional 100g · h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 CT/week (95% confidence inter-
val [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert CT, indicating faster
clearance ofMycobacterium tuberculosisDNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may
be useful as a dynamic measure of TB treatment response.
The best available intermediate markers of tuberculosis (TB)treatment response for individual patient monitoring and
for TB drug development are currently sputum smear micros-
copy and sputum culture conversion. Sputum culture at inter-
mediate time points, although demonstrated in prior studies to
have some utility for predicting treatment success or failure
(1), has been called into question as a surrogate marker, given
its limited ability to predict relapse (2, 3). Sputum smear mi-
croscopy at 2 months, though currently recommended by the
World Health Organization (WHO), has a sensitivity as low as
24% for relapse (4).
The Xpert MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA),
an automated, cartridge-based semiquantitative PCR (sqPCR) as-
say targeting the rpoB locus of Mycobacterium tuberculosis DNA,
received WHO endorsement as a preferred TB diagnostic in 2010
(5, 6). Since endorsement, a massive rollout of Xpert has been
undertaken, delivering the assay to 116 countries, with over 10
million cartridges procured under concessional pricing in the
public sector (5). According to WHO estimates, the costs of
Xpert are similar to those of mycobacterial culture, but large-
scale implementation of Xpert will not require the infrastruc-
ture of specialized laboratories and personnel training needed
for mycobacterial culture technologies (7). Some national TB
programs have already replaced sputum smear microscopy
with Xpert as the primary diagnostic (8–11). It is thus impor-
tant to determine if there is a role for serial Xpert assays in
monitoring TB treatment response. Previous studies have
demonstrated that the quantitative output of Xpert in cycle
threshold (CT) values, indicating the number of rounds of PCR
amplification required to detect M. tuberculosis DNA, correlates
closely with bacillary burden in sputum in vitro (12). While the
routine Xpert results report includes only a semiquantitative
output (negative, very low, low, medium, high), the numerical
CT also may be obtained from the GeneXpert platform by an
algorithm without additional software. A recent study evaluat-
ing the longitudinal use of Xpert in clinical trial participants on
TB therapy found high sensitivity but very low specificity for
the assay; however, this study interpreted Xpert results as a
dichotomous marker (i.e., M. tuberculosis DNA detected versus
not detected) compared to binary microbiologic measures of TB
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treatment response (i.e., smear and culture results) (13). Another
study found an association between numerical CT and same-day
culture status and with treatment failure (14).
In this study, we evaluated serial Xpert sputum assays over 12
weeks of TB treatment within a cohort of patients enrolled in
Tuberculosis Trials Consortium (TBTC) study 29X, a phase 2 ran-
domized clinical trial comparing dose-escalating rifapentine-
based regimens with standard rifampin-based therapy for drug-
sensitive TB (15). We took advantage of the parent study’s
pharmacokinetic (PK) measures to identify clinical and treat-
ment-related factors associated with Xpert CT trajectory.
MATERIALS AND METHODS
Study sites, population, and treatments. Of the 20 international sites
participating in TBTC study 29X (ClinicalTrials registration number
NCT00694629), the Xpert substudy consecutively enrolled consenting
participants at 10 sites in 5 countries: Barcelona, Spain; Lima, Peru;
Kisumu, Kenya; Soweto and Cape Town, South Africa; San Francisco,
California, and 4 sites in Texas, United States. Adult (age, 18 years)
ambulatory patients with smear-positive pulmonary TB participating in
study 29X were enrolled. All participants underwent HIV testing. Partic-
ipants were randomly assigned to one of four treatment arms, containing
rifapentine at 10, 15, or 20 mg/kg of body weight or rifampin at 10 mg/kg
in addition to isoniazid, ethambutol, and pyrazinamide at standard doses
during the intensive phase. After completing intensive-phase treatment,
participants continued treatment with a conventional continuation-
phase regimen, typically isoniazid plus rifampin for 4 additional months
(15, 16). Informed consent was obtained from all participants for the parent
trial, and the study was approved by institutional review boards at the Centers
for Disease Control and Prevention and at each participating site. None of the
Xpert data obtained for this substudy were used for clinical decision-making.
Detailed clinical, radiologic, and laboratory-specific information was re-
corded on standardized case record forms and captured using double data
entry as part of the parent trial. A standardized protocol was developed and
used at all 10 participating sites involved in the longitudinal evaluation of
Xpert. Information regarding the design, conduct, and results of TBTC study
29X has been published previously (15).
Sputum sample collection and processing. Participants provided
sputum samples at time of enrollment (pretreatment) and at weeks 2, 4, 6,
8, and 12 of anti-TB therapy. Per protocol, a single specimen was obtained
at all time points, except for week 8 when two separate specimens were
obtained. Sputum induction was performed for patients unable to expec-
torate. Laboratory technicians recorded the volume (which ranged to a max-
imum of 10 ml) and quality of each sputum sample (salivary, mucoid, or
purulent) and then performed decontamination with conventional 1% to 2%
N-acetylcysteine and sodium hydroxide methods (final NaOH concentra-
tion, 1% to 2%) (17). Centrifugation was performed for 15 min at 3,000 g,
and the resulting pellet was resuspended with a phosphate buffer solution, pH
6.8, to a total volume of 2 to 2.5 ml (17). For smear microscopy, 0.1 ml of the
suspension was used, and 0.2 ml and 0.5 ml were inoculated into solid (Low-
enstein-Jensen) and liquid (Bactec mycobacterial growth indicator tube
[MGIT] 960; Becton Dickinson, Sparks, MD, USA) culture media, respec-
tively. The residual sputum pellet was tested with Xpert using the standard-
ized procedures described below.
Xpert MTB/RIF procedure. Following sampling for other microbio-
logical outcomes, 0.5 ml of the resuspension from the residual pellet was
combined with Sample Reagent (SR; Cepheid) in a 1:3 ratio, and 2 ml of
sample in SR were pipetted into an Xpert MTB/RIF test cartridge. The
cartridge was loaded into the instrument, and Xpert testing was per-
formed automatically by instrument and software according to the man-
ufacturer’s recommendations. For the five target probes within the rpoB
sequence, the sqPCR per-probe threshold cycle was archived and con-
verted to tabular format for analysis. The assay was validated with the use
of positive controls (provided by the manufacturer to each participating
laboratory), prepared by spiking with a known M. tuberculosis DNA copy
number, in order to verify the correct performance of the assay for the
various targets.
Statistical analysis. Longitudinal Xpert CT data were modeled using a
nonlinear mixed effects approach and performed in NONMEM version
7.3 (Icon Development Solutions, Ellicott City, MD, USA). The likelihood
ratio test, which compares2 log likelihood between two nested models,
was used to assess significance. Of the five probe CT values reported for
each assay, the minimum CT value was used in our analysis as recom-
mended by the manufacturer. A likelihood-based method (M3) was im-
plemented to handle upper censoring for sputum samples in which no M.
TABLE 1 Demographic and clinical characteristics of Xpert study
participants at time of enrollment (n 115)
Characteristic
No. of
participants
% of
participants
Male 77 67
Age
18–35 54 47
36–50 29 25
50 32 28
HIV infected 8 7
CD4 lymphocyte count (cells/mm3)
50 1 1
50–199 0 0
200–350 1 1
350 6 5
History of smoking 59 51
Body mass index (kg/m2)
16 3 3
16–18.5 37 32
18.6–25 60 52
25 11 10
Not reported 4 3
Race
Asian 3 3
Black 75 65
White 25 22
Multiracial 2 2
Not reported 10 9
Cavitation on chest radiograph at enrollment 85 74
Chest radiograph class
No cavities 30 26
Cavities,4 cm in aggregate 40 35
Cavities,4 cm in aggregate 45 39
Treatment arm
Rifampin (10 mg/kg/day) 27 23
Rifapentine (10 mg/kg/day) 34 30
Rifapentine (15 mg/kg/day) 25 22
Rifapentine (20 mg/kg/day) 29 25
Culture negative at week 8
Solid medium 89 77
Liquid medium 79 69
Both solid and liquid media 78 68
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tuberculosis DNA was detected (18). For those few patients who had mul-
tiple assay results at a single time point other than 8 weeks, replicate data
were retained in our final model to increase precision. Analyses conducted
with the exclusion of these replicates did not affect results. CT trajectories
were best fit by a model, whereas baseline CT and linear rate of change in
CT could be estimated. A baseline model for the control (rifampin) arm
was developed first, followed by the addition of dose-ranging rifapentine
data. Comparative CT changes for rifapentine versus rifampin were mod-
eled as functions of regimen (dose measured in milligrams per kilogram),
dose (600 mg, 900 mg, or 1,200 mg of rifapentine), or drug exposure as
measured by area under the plasma concentration-time curve (AUC),
which was estimated from a population pharmacokinetic model incorpo-
rating plasma rifapentine levels measured at a single time point (15).
RESULTS
A total of 786 sputum samples were obtained from 115 consecu-
tively enrolled study participants from weeks 0 to 12 after ini-
tiation of TB treatment. Of these specimens, 217 contained no
detectable M. tuberculosisDNA and were subject to upper censor-
ing. The bulk of undetectable specimens occurred toward the end
of the study period; 30% of week 8 samples and 40% of week 12
samples were Xpert negative. Table 1 describes the demographic
and clinical characteristics of the study participants.
Clinical factors affectingCT trajectory. In univariate analysis,
smoking within the past year and disease extent on chest radio-
graph were the only clinical covariates that had a significant asso-
ciation with Xpert results. Participants reporting any history of
smoking had a lower baseline CT, indicating a higher bacterial
burden at the time of enrollment (P 0.01), than those who did
not smoke. There were no subsequent differences in rate of change
in CT based on smoking status. Subjects with a baseline chest ra-
diograph indicating high disease extent (defined as more than half
of the chest affected by TB) had a lower baselineCT and a lowerCT
slope on treatment, indicating higher bacterial burden at baseline
(P  0.05) and a slower subsequent rate of change (P  0.04);
however, in multivariate analyses, associations between disease
extent on chest radiograph and rate of CT change were no longer
significant.
Treatment arm, drug dose, and drug exposure effects on CT
trajectory. Median baseline CT was estimated in our model to be
19.81 (95% confidence interval [CI],18.64 to 20.98) with 24%
between-subject variability. Figure 1 depicts raw CT results across
treatment arms, highlighting these significant within-subject and
between-subject variabilities. From week 0 to week 12, the median
rate of change in CT for the rifampin arm was estimated to be 0.88
CT/week (95% CI, 0.61 to 1.14). Comparing participants who re-
ceived rifampin-based therapy with all of those who received rifa-
pentine-based therapy, irrespective of the dosing, a significant dif-
ference in CT trajectory was found, with faster M. tuberculosis
DNA clearance in those receiving rifapentine at a median rate of
change of 1.18CT/week (P 0.05). However, the between-subject
variability across all treatment arms was high (coefficient of vari-
ation, 102%).
Since the difference in CT trajectory between those who re-
ceived rifampin and those who received rifapentine may have
been due to the higher dosages of rifapentine administered
during the study, we investigated the direct association of drug
exposure with M. tuberculosis DNA clearance. Using a popula-
FIG 1 Cycle threshold (CT) trajectories for 115 individual study participants (gray lines) across treatment arms, demonstrating large intrasubject and intersub-
ject variability over time. The estimated mean CT for each treatment arm (colored lines) rises over time, reflecting clearance of M. tuberculosis DNA with
treatment. No significant difference can be seen in overall CT trajectory between treatment arms.
Jayakumar et al.
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tion pharmacokinetic model developed for the parent trial,
rifapentine exposure (AUC) was derived for each individual
(15). We found that the derived AUC was a significant predic-
tor of the rate of change in CT (P  0.02). The estimated in-
crease in CT slope for every additional 100 g · h/ml of rifap-
entine AUC was 0.11 CT/week (95% CI, 0.05 to 0.17). Figure 2
depicts the positive correlation between CT slope and median
rifapentine AUC. However, CT trajectories did not vary signif-
icantly across rifapentine treatment arms (1.34, 1.38, and 1.10
CT/week for rifapentine at 10 mg/kg, 15 mg/kg, and 20 mg/kg,
respectively; P  0.25) or across administered dosage groups
(1.19, 1.09, and 1.10 CT/week at 600, 900, or 1,200 mg, respec-
tively; P  0.13). Study 29X showed a similar association be-
tween treatment and sputum culture conversion in the liquid
culture medium, in which higher rifapentine exposure, but not
treatment arm (weight-based rifapentine dose) or flat rifapen-
tine dose, was significantly associated with faster culture con-
version (15). Table 2 shows previously published data by Dor-
man et al. (15) from their larger parent study data set cohort
alongside our results from our subset of 115 study participants
to demonstrate the consistent significance of rifamycin expo-
sure across monitoring methodologies.
Effects of baseline CT on subsequent rate of change. When
upper-censored data were excluded, a negative correlation coeffi-
cient of 0.57 (relative standard error, 15%) was found between
baseline CT and rate of change in CT over 12 weeks, indicating
faster clearance of M. tuberculosis DNA in individuals with higher
baselineM. tuberculosisDNA burdens. However, this effect was no
longer seen when censored data were included.
DISCUSSION
In this study, we have shown that increasing rifapentine exposure
is associated with faster M. tuberculosis DNA clearance, as mea-
sured by longitudinal Xpert CT data, over the first 12 weeks of
therapy. The association found between rifapentine exposure and
longitudinal Xpert CT trajectory is consistent with the biologically
plausible idea that higher serum levels of effective medication lead
to faster bacterial killing and supports the ability of the Xpert
MTB/RIF assay to measure such a relationship. In addition, our
study demonstrates the feasibility of using PK parameters as a
novel alternative to comparing the assay’s predictive perfor-
mance with intermediate microbiologic outcomes, which can
be unreliable and insensitive for predicting relapse. Interest-
ingly, the results in this substudy mirror the data from the
parent study on the relationship between drug exposure and
culture conversion, suggesting that despite Xpert’s lower spec-
ificity for viable mycobacteria, the overall behavior of the assay
is similar to that of sputum culture in longitudinal use (15). We
also found that clinical factors, including smoking status and
radiographic extent of disease were associated with Xpert CT
measurements in a univariate analysis. While these factors were
not retained in our final statistical model based on predefined
criteria, this nonetheless suggests that greater mycobacterial
burden associated with these important clinical features is ad-
ditionally quantified by the Xpert assay. Finally, we found that
Xpert CT measurements demonstrate a high degree of within-
subject and between-subject variability. Variation in Xpert’s
semiquantitative estimates among sputum samples within the
same acid-fast bacilli grade has been previously described (19).
Such variability is inherent in any quantitative sputum-based
assay in which specimen collection depends on the strength of
the cough, method of induction or expectoration, and many
other clinical factors. Yet, even given this variability, the asso-
ciation between M. tuberculosis DNA clearance and rifapentine
exposure was significant.
We found that a lower CT (corresponding to higher M. tuber-
culosis DNA load in sputum) at baseline may predict faster clear-
ance over the course of early treatment. The Xpert MTB/RIF tech-
nology incorporates a novel filtering mechanism that primarily
allows intact bacilli to be assayed in the sample, yet concerns have
remained regarding the measurement of DNA from nonviable
M. tuberculosis if Xpert is used in patients while on TB treatment.
Our results suggest that the assay may in fact be able to measure
the rapid killing of mycobacteria seen early in treatment. How-
TABLE 2 Overall P values for comparisons of Xpert CT slope
obtained in 115 substudy participants as compared to the time to
stable culture conversion on a solid medium and time to stable
culture conversion on a liquid medium in 195 participants in the
parent clinical trial by treatment arm (rifapentine 10, 15, and 20 mg/
kg versus rifampin; rifapentine dose (600 mg, 900 mg, 1,200 mg
versus rifampin); and rifapentine exposure (area under the
concentration time-curve tertiles)
Variable
Xpert CT
slopea
(n 115)
Time to stable
culture conversion
on solid mediumb
(n 195)
Time to stable
culture conversion
on liquid mediumb
(n 195)
Treatment arm 0.25 0.01 0.32
Rifapentine dose 0.13 0.01 0.38
Rifapentine exposure 0.02 0.001 0.001
a P values were derived using the likelihood ratio test based on the current substudy of
115 patients.
b P values were reported previously by Dorman et al. in Supplemental Table E7 (in
reference 15) based on parent study cohort.
FIG 2 Relationship between CT slope and AUC (g · hr/ml) in 115 study
participants. As rifapentine exposure increases, rate of change in CT also in-
creases, indicating faster M. tuberculosis DNA clearance.
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ever, this association no longer holds true when upper-cen-
sored data, i.e., samples in which M. tuberculosis DNA is unde-
tectable, are included. It has been shown that a minimum of
100 to 150 bacteria are required in the Xpert cartridge to clas-
sify a sample as positive for M. tuberculosis (12). This effect may
therefore be subject to bias introduced by the inclusion of only
observable data, and speaks to the importance of statistical
methods that can incorporate nonobservable data, when deal-
ing with data sets that have a high proportion of values outside
the limits of quantification.
Our findings do not answer the question of how Xpert can
be used to monitor the individual patient and predict the risk of
poor treatment outcome, particularly treatment relapse. It is
clear that Xpert MTB/RIF, when interpreted as a dichotomous
test toward the end of the intensive phase of TB treatment, is
insufficiently specific for identifying patients at high risk for
poor long-term outcomes. Our findings mirror results previ-
ously published by Friedrich et al., in which Xpert remained
positive in approximately 80% and 60% of patients at 8 and 12
weeks (13). However, it remains possible that Xpert cycle
thresholds near or at the end of treatment at weeks 20 and
beyond, when TB cultures are negative, may be informative for
determining the risk of relapse.
Our study has limitations. The study contained a small propor-
tion of HIV-infected participants, limiting its generalizability
to high-HIV-prevalence populations. Second, and impor-
tantly, the parent study lacked long-term follow-up after treat-
ment completion, and this precluded us from evaluating
whether Xpert monitoring during treatment could predict a
durable cure. Conversely, this study benefits from being nested
within a clinical trial, which provided rigorously standardized
and monitored study conditions, including the use of directly
observed therapy. In addition, to our knowledge, this is the first
published study to include pharmacokinetic parameters in the
modeling of Xpert results. Finally, our study included patients
from 10 international sites, comprising the most diverse pop-
ulation yet studied for Xpert longitudinal monitoring. In our
results, study site was not associated with change in Xpert CT,
suggesting that site-specific technical factors did not contribute
to our findings.
In sum, this study demonstrates that rifapentine exposure is
associated with rate of change in quantitative Xpert CT over the
first 12 weeks of TB therapy, suggesting that CT may be a useful
tool for monitoring treatment effect. This mirrors data from the
parent trial, study 29X, which indicated faster sputum culture
conversion based on rifapentine exposure rather than flat or
weight-based dosage. Moreover, Xpert utilizes molecular technol-
ogy that is quick, easily interpretable, and not prone to contami-
nation compared with culture. Further evaluation of Xpert in a
larger study with long-term follow-up after cessation of treat-
ment, including later Xpert measurements, pharmacokinetics,
and measures of clinically meaningful treatment outcomes, would
be needed to determine the performance of this technology for
predicting relapse.
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